Nasdaq · CIK 0001853921
SCTX Scribe Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jul 29, 2026. Close $19.12 on Oct 13, 2026, +18% from the 52-week low and -49% from the high.
In brief
Scribe Therapeutics, Inc. (SCTX) has 13 SEC Form 4 filings on file from 11 insiders, the latest filed on Jul 29, 2026. In the last 90 days insiders made 6 open-market buys worth $71M and 0 open-market sells worth $0, net +$71M.
6 open-market trades have been scored at SCTX. The newest: AH Bio Fund II, L.P. (10% owner) bought $5.0M of stock on Jul 27, 2026, filed Jul 29, 2026, scored 50 (moderate). The largest of the 6 shown: Behzad Aghazadeh (director and 10% owner) bought $36M on Jul 24, 2026, scored 65 (notable). 6 insiders bought within 14 days of each other around Jul 27, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Scribe Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | AH Bio Fund II, L.P. owner buy | $5.0M 333,333 shares | +16% | - | |
| 65Notable | Carl L Gordon director buy | $15M 1,000,000 shares | +287% | - | |
| 60Notable | Orbimed Advisors LLC director buy | $15M 1,000,000 shares | +287% | - | |
| 65Notable | Behzad Aghazadeh director, owner, other buy | $36M 2,391,238 shares | +343% | - | |
| 44Moderate | Svetlana Lucas Chief Business Officer buy | $45k 3,000 shares | - | - | |
| 51Moderate | David Parrot Chief Financial Officer buy | $40k 2,666 shares | - | - |
Transactions
Every row filed, 35 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | AH Bio Fund II, L.P. owner | CConversion Common Stockindirect: By AH Bio Fund II, L.P. | +2,051,742 | - | - | 2,051,742 | Jul 29, 2026 |
| Jul 27, 2026 | Jennifer A Doudna owner | CConversion Common Stock | +12,511 | - | - | 603,547 | Jul 29, 2026 |
| Jul 27, 2026 | Carl L Gordon director | CConversion Common Stockindirect: See footnotes | +348,825 | - | - | 348,825 | Jul 29, 2026 |
| Jul 27, 2026 | Orbimed Advisors LLC director | CConversion Common Stockindirect: See footnotes | +348,825 | - | - | 348,825 | Jul 29, 2026 |
| Jul 27, 2026 | AH Bio Fund II, L.P. owner | CConversion Common Stockindirect: By AH Bio Fund III, L.P. | +697,650 | - | - | 697,650 | Jul 29, 2026 |
| Jul 27, 2026 | Jennifer A Doudna owner | CConversion Series A-1 Preferred Stockderivative | -74,088 | - | - | 0 | Jul 29, 2026 |
| Jul 27, 2026 | Carl L Gordon director | POpen-market purchase Common Stockindirect: See footnotes | +1,000,000 | $15.00 | $15M | 1,348,825 | Jul 29, 2026 |
| Jul 27, 2026 | Orbimed Advisors LLC director | POpen-market purchase Common Stockindirect: See footnotes | +1,000,000 | $15.00 | $15M | 1,348,825 | Jul 29, 2026 |
| Jul 27, 2026 | AH Bio Fund II, L.P. owner | POpen-market purchase Common Stockindirect: By AH Bio Fund II, L.P. | +333,333 | $15.00 | $5.0M | 2,385,075 | Jul 29, 2026 |
| Jul 27, 2026 | Carl L Gordon director | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -2,065,672 | $0.00 | $0 | 0 | Jul 29, 2026 |
| Jul 27, 2026 | Orbimed Advisors LLC director | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -2,065,672 | $0.00 | $0 | 0 | Jul 29, 2026 |
| Jul 27, 2026 | AH Bio Fund II, L.P. owner | CConversion Series A Preferred Stockderivativeindirect: By AH Bio Fund II, L.P. | -12,150,003 | $0.00 | $0 | 0 | Jul 29, 2026 |
| Jul 27, 2026 | AH Bio Fund II, L.P. owner | CConversion Series B Preferred Stockderivativeindirect: By AH Bio Fund III, L.P. | -4,131,344 | $0.00 | $0 | 0 | Jul 29, 2026 |
| Mar 13, 2026 | Brett Staahl owner | AGrant or award Stock Option (Right to Buy)derivative | +4,755 | $0.00 | $0 | 4,755 | Jul 28, 2026 |
| Jul 24, 2026 | Behzad Aghazadeh director, owner, other | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: See footnotes | +2,333,333 | $15.00 | $35M | 3,030,983 | Jul 28, 2026 |
| Jul 24, 2026 | Behzad Aghazadeh director, owner, other | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: See footnotes | +50,000 | $22.31 | $1.1M | 3,080,983 | Jul 28, 2026 |
| Jul 23, 2026 | Brett Staahl owner | AGrant or award Stock Option (Right to Buy)derivative | +19,385 | $0.00 | $0 | 19,385 | Jul 28, 2026 |
| Jul 28, 2026 | Behzad Aghazadeh director, owner, other | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: See footnotes | +7,905 | $18.25 | $144k | 3,088,888 | Jul 28, 2026 |
| Jul 23, 2026 | Brett Staahl owner | AGrant or award Performance-based Stock Option (Right to Buy)derivative | +19,385 | $0.00 | $0 | 19,385 | Jul 28, 2026 |
| Jul 23, 2026 | Svetlana Lucas Chief Business Officer | POpen-market purchase Common Stockindirect: By Spouse | +3,000 | $15.00 | $45k | 3,000 | Jul 27, 2026 |
| Jul 23, 2026 | David Parrot Chief Financial Officer | POpen-market purchase Common Stockindirect: By Spouse | +1,333 | $15.00 | $20k | 1,333 | Jul 27, 2026 |
| Jul 23, 2026 | James Dean Watson director | AGrant or award Stock Option (Right to Buy)derivative | +14,725 | $0.00 | $0 | 14,725 | Jul 27, 2026 |
| Jul 23, 2026 | Carl L Gordon director | AGrant or award Stock Option (Right to Buy)derivative | +14,725 | $0.00 | $0 | 14,725 | Jul 27, 2026 |
| Jul 23, 2026 | Joshua Bleharski director | AGrant or award Stock Option (Right to Buy)derivative | +14,725 | $0.00 | $0 | 14,725 | Jul 27, 2026 |
| Mar 13, 2026 | Benjamin L. Oakes President, CEO | AGrant or award Stock Option (Right to Buy)derivative | +12,969 | $0.00 | $0 | 12,969 | Jul 27, 2026 |
| Jul 23, 2026 | Behzad Aghazadeh director, other | AGrant or award Stock Option (Right to Buy)derivative | +14,725 | $0.00 | $0 | 14,725 | Jul 27, 2026 |
| Jul 23, 2026 | Benjamin L. Oakes President, CEO | AGrant or award Stock Option (Right to Buy)derivative | +264,784 | $0.00 | $0 | 264,784 | Jul 27, 2026 |
| Jul 23, 2026 | David Parrot Chief Financial Officer | POpen-market purchase Common Stockindirect: By Child | +1,333 | $15.00 | $20k | 1,333 | Jul 27, 2026 |
| Mar 13, 2026 | Svetlana Lucas Chief Business Officer | AGrant or award Stock Option (Right to Buy)derivative | +9,547 | $0.00 | $0 | 9,547 | Jul 27, 2026 |
| Jul 23, 2026 | Svetlana Lucas Chief Business Officer | AGrant or award Stock Option (Right to Buy)derivative | +109,426 | $0.00 | $0 | 109,426 | Jul 27, 2026 |
| Jul 23, 2026 | Benjamin L. Oakes President, CEO | AGrant or award Performance-based Stock Option (Right to Buy)derivative | +429,599 | $0.00 | $0 | 429,599 | Jul 27, 2026 |
| Mar 13, 2026 | David Parrot Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +8,909 | $0.00 | $0 | 8,909 | Jul 27, 2026 |
| Jul 23, 2026 | Svetlana Lucas Chief Business Officer | AGrant or award Performance-based Stock Option (Right to Buy)derivative | +109,426 | $0.00 | $0 | 109,426 | Jul 27, 2026 |
| Jul 23, 2026 | David Parrot Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +109,426 | $0.00 | $0 | 109,426 | Jul 27, 2026 |
| Jul 23, 2026 | David Parrot Chief Financial Officer | AGrant or award Performance-based Stock Option (Right to Buy)derivative | +109,426 | $0.00 | $0 | 109,426 | Jul 27, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- AH Bio Fund II, L.P.owner
- Behzad Aghazadehdirector, owner, other
- Joshua Bleharskicfo, officer, director
- Jennifer A Doudnadirector, owner
- Carl L Gordondirector, owner
- Svetlana LucasChief Business Officer
- Orbimed Advisors LLCdirector, owner
- Benjamin L. OakesPresident, CEO
- David ParrotChief Financial Officer
- Brett Staahlowner
- James Dean Watsondirector
Questions about SCTX
Answered from the filings on this page, as of the latest one.
Are insiders buying SCTX?
As of Jul 29, 2026, SEC Form 4 filings show 6 open-market buys worth $71M by 6 insiders and 0 open-market sells worth $0 by 0 insiders at Scribe Therapeutics, Inc. in the last 90 days, net +$71M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade SCTX on the open market?
AH Bio Fund II, L.P. (10% owner) bought $5.0M of SCTX on Jul 27, 2026 and filed the Form 4 on Jul 29, 2026. InsiderTell scored 50 (moderate), with 6 insiders on the same side within 14 days.
How many insiders file Form 4 at Scribe Therapeutics, Inc.?
11 people have filed a Form 4 at Scribe Therapeutics, Inc., among them AH Bio Fund II, L.P. (10% owner), Behzad Aghazadeh (director and 10% owner), Joshua Bleharski (CFO and director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.